Lipocine Reports Presentation of LPCN 1021 Data at SMSNA Meeting

Lipocine Inc. LPCN, a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency or absence of endogenous testosterone ("hypogonadism"), will be presented at the 21st Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Las Vegas, NV. Presentation/poster details are as follows: Title: Dose Titration and Safety of Oral Testosterone (LPCN 1021) in Hypogonadal Men: Results from the SOAR Study (#030) Date: November 20th Time: 3:15 pm PST (Poster: 3:00 - 4:00 pm PST) Presenter: Mohit Khera, MD Associate Professor, Urology Baylor College of Medicine Houston, TX, US Director, Laboratory for Andrology Research Medical Director, Houston Hospital for Specialized Surgery Title: Assessment of Fasting and Varying Meal Fat Content on the Bioavailability of Testosterone from Oral Testosterone Undecanoate (LPCN 1021) in Hypogonadal Men (#036) Date: November 20th Time: 3:45 pm PST (Poster: 3:00 - 4:00 pm PST) Presenter: Mohit Khera, MD Title: Efficacy and Pharmacokinetics of Oral Testosterone (LPCN 1021) in Hypogonadal Men (#028) Date: November 20th Time: 3:05 pm PST (Poster: 3:00 - 4:00 pm PST) Presenter: Irwin Goldstein, MD Director, San Diego Sexual Medicine Director, Sexual Medicine, Alvarado Hospital, San Diego, CA Clinical Professor of Surgery, University of California at San Diego Editor-in-Chief, Sexual Medicine Reviews President-Elect, International Society for the Study of Women's Sexual Health Editor Emeritus, The Journal of Sexual Medicine Editor Emeritus, International Journal of Impotence Research